Skip to main content

Pfost Dale R's Form 4 filing

Chemomab Therapeutics Ltd. (CMMB) · filed Mar 15, 2022

Accession no.
0001178913-22-001120
Filed
Mar 15, 2022
Trade date
Oct 25, 2021-Mar 14, 2022
Filing delay
141 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $9.94K. It was filed 141 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Pfost Dale RCIK 0001394663Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 14, 2022American Depositary SharesPPurchaseAcquired+1,800$3.98+$7,1641,800Direct
Mar 14, 2022American Depositary SharesPPurchaseAcquired+700$3.97+$2,7792,500Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 25, 2021American Depositary SharesAGrant or awardAcquired+459,353$0.00$0459,353Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)